Nuvation Bio ($NUVB) Posts Strong Q3 Revenue as IBTROZI Launch Builds Momentum Nuvation Bio reported $45.0 million in total third-quarter 2026 revenue, includi

Nuvation Bio ($NUVB) Posts Strong Q3 Revenue as IBTROZI Launch Builds Momentum Nuvation Bio reported $45.0 million in total third-quarter 2026 revenue, including $27.5 million in net product revenue for its drug IBTROZI (taletrectinib). Net loss narrowed to $41.9 million, or $0.12 per share, compa…